Azilsartan: Current Evidence and Perspectives in Management of Hypertension

Overview

Journal Int J Hypertens

Publisher Wiley

Date 2019 Dec 31

PMID 31885897

Citations 4

Authors

Akshyaya Pradhan

Ashish Tiwari

Rishi Sethi

Affiliations

Soon will be listed here.

Abstract

Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.

Citing Articles

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study).

Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y J Clin Hypertens (Greenwich). 2024; 27(1):e14938.

PMID: 39632589 PMC: 11771805. DOI: 10.1111/jch.14938.

Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea.

Kim H, Son N, Jeong D, Yoo M, Choi I, Choi W Drug Saf. 2024; 47(7):673-686.

PMID: 38512445 PMC: 11182788. DOI: 10.1007/s40264-024-01418-4.

Gastroprotective Effect of Azilsartan Through Ameliorating Oxidative Stress, Inflammation, and Restoring Hydroxyproline, and Gastrin Levels in Ethanol-Induced Gastric Ulcer.

Hama Amin R, Aziz T J Inflamm Res. 2022; 15:2911-2923.

PMID: 35592072 PMC: 9113664. DOI: 10.2147/JIR.S365090.

Azilsartan protects against hyperglycemia-induced hyperpermeability of the blood-brain barrier.

Han J, Tang H, Yao L, Jin E, Pan W, Chen S Bioengineered. 2021; 12(1):3621-3633.

PMID: 34266350 PMC: 8806574. DOI: 10.1080/21655979.2021.1948950.

Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.

Heimfarth L, Dos Santos M, Barreto-Filho J, Barreto A, Macedo F, Araujo A EXCLI J. 2021; 20:252-275.

PMID: 33628162 PMC: 7898045. DOI: 10.17179/excli2021-3412.

References

Kario K, Hoshide S . Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study. Hypertension. 2015; 65(4):729-35. DOI: 10.1161/HYPERTENSIONAHA.114.04935. View

Gradman A, Basile J, Carter B, Bakris G . Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011; 13(3):146-54. PMC: 8673364. DOI: 10.1111/j.1751-7176.2010.00397.x. View

Bakris G, Sica D, Weber M, White W, Roberts A, Perez A . The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011; 13(2):81-8. PMC: 8673073. DOI: 10.1111/j.1751-7176.2010.00425.x. View

Gitt A, Bramlage P, Potthoff S, Baumgart P, Mahfoud F, Buhck H . Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016; 16:56. PMC: 4784379. DOI: 10.1186/s12872-016-0222-6. View

Prabhakaran D, Jeemon P, Ghosh S, Shivashankar R, Ajay V, Kondal D . Prevalence and incidence of hypertension: Results from a representative cohort of over 16,000 adults in three cities of South Asia. Indian Heart J. 2017; 69(4):434-441. PMC: 5560901. DOI: 10.1016/j.ihj.2017.05.021. View

Timmermans P, Duncia J, Carini D, Chiu A, Wong P, Wexler R . Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995; 9 Suppl 5:S3-18. View

Cushman W, Bakris G, White W, Weber M, Sica D, Roberts A . Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012; 60(2):310-8. DOI: 10.1161/HYPERTENSIONAHA.111.188284. View

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

Bakris G, Sica D, White W, Cushman W, Weber M, Handley A . Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012; 125(12):1229.e1-1229.e10. DOI: 10.1016/j.amjmed.2012.05.023. View

10.

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

11.

Lim S, Vos T, Flaxman A, Danaei G, Shibuya K, Adair-Rohani H . A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2224-60. PMC: 4156511. DOI: 10.1016/S0140-6736(12)61766-8. View

12.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360(9349):1903-13. DOI: 10.1016/s0140-6736(02)11911-8. View

13.

Rakugi H, Enya K, Sugiura K, Ikeda Y . Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012; 35(5):552-8. PMC: 3348575. DOI: 10.1038/hr.2012.8. View

14.

Haller H, Ito S, Izzo Jr J, Januszewicz A, Katayama S, Menne J . Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364(10):907-17. DOI: 10.1056/NEJMoa1007994. View

15.

Sica D, White W, Weber M, Bakris G, Perez A, Cao C . Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011; 13(7):467-72. PMC: 8108745. DOI: 10.1111/j.1751-7176.2011.00482.x. View

16.

Sezai A, Osaka S, Yaoita H, Arimoto M, Hata H, Shiono M . Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). Ann Thorac Cardiovasc Surg. 2016; 22(3):161-7. PMC: 4909997. DOI: 10.5761/atcs.oa.16-00054. View

17.

White W, Weber M, Sica D, Bakris G, Perez A, Cao C . Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011; 57(3):413-20. DOI: 10.1161/HYPERTENSIONAHA.110.163402. View

18.

Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15):1547-59. DOI: 10.1056/NEJMoa0801317. View

19.

Whelton P, Carey R, Aronow W, Casey Jr D, Collins K, Himmelfarb C . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association.... Hypertension. 2017; 71(6):1269-1324. DOI: 10.1161/HYP.0000000000000066. View

20.

Takagi H, Mizuno Y, Niwa M, Goto S, Umemoto T . A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2013; 37(5):432-7. DOI: 10.1038/hr.2013.142. View